These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 39409080)

  • 1. Plasma Proteomic Biomarkers in Alzheimer's Disease and Cardiovascular Disease: A Longitudinal Study.
    Theeke LA; Liu Y; Wang S; Luo X; Navia RO; Xiao D; Xu C; Wang K; The Alzheimer And Disease Neuroimaging Initiative
    Int J Mol Sci; 2024 Oct; 25(19):. PubMed ID: 39409080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of Angiotensin-Converting Enzyme and Apolipoproteins Are Associated with Alzheimer's Disease and Cardiovascular Diseases.
    Xu C; Garcia D; Lu Y; Ozuna K; Adjeroh DA; Wang K; On Behalf Of The Alzheimer's Disease Neuroimaging Initiative
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Longitudinal Cognitive Decline and Alzheimer's Conversion in Mild Cognitive Impairment Patients Based on Plasma Biomarkers.
    Park MK; Ahn J; Kim YJ; Lee JW; Lee JC; Hwang SJ; Kim KC
    Cells; 2024 Jun; 13(13):. PubMed ID: 38994939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low testosterone levels relate to poorer cognitive function in women in an APOE-ε4-dependant manner.
    Dratva MA; Banks SJ; Panizzon MS; Galasko D; Sundermann EE;
    Biol Sex Differ; 2024 Jun; 15(1):45. PubMed ID: 38835072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral Markers of Vascular Endothelial Dysfunction Show Independent but Additive Relationships with Brain-Based Biomarkers in Association with Functional Impairment in Alzheimer's Disease.
    Drake JD; Chambers AB; Ott BR; Daiello LA;
    J Alzheimers Dis; 2021; 80(4):1553-1565. PubMed ID: 33720880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower Serum Calcium as a Potentially Associated Factor for Conversion of Mild Cognitive Impairment to Early Alzheimer's Disease in the Japanese Alzheimer's Disease Neuroimaging Initiative.
    Sato K; Mano T; Ihara R; Suzuki K; Tomita N; Arai H; Ishii K; Senda M; Ito K; Ikeuchi T; Kuwano R; Matsuda H; Iwatsubo T; Toda T; Iwata A;
    J Alzheimers Dis; 2019; 68(2):777-788. PubMed ID: 30814351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging proteomics for diagnosis, monitoring and prediction of Alzheimer's disease.
    Nazeri A; Ganjgahi H; Roostaei T; Nichols T; Zarei M;
    Neuroimage; 2014 Nov; 102 Pt 2(Pt 2):657-65. PubMed ID: 25173418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset.
    Johnstone D; Milward EA; Berretta R; Moscato P;
    PLoS One; 2012; 7(4):e34341. PubMed ID: 22485168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What Are the Reliable Plasma Biomarkers for Mild Cognitive Impairment? A Clinical 4D Proteomics Study and Validation.
    Hou Z; Sun A; Li Y; Song X; Liu S; Hu X; Luan Y; Guan H; He C; Sun Y; Chen J
    Mediators Inflamm; 2024; 2024():7709277. PubMed ID: 38883967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harnessing peripheral DNA methylation differences in the Alzheimer's Disease Neuroimaging Initiative (ADNI) to reveal novel biomarkers of disease.
    Vasanthakumar A; Davis JW; Idler K; Waring JF; Asque E; Riley-Gillis B; Grosskurth S; Srivastava G; Kim S; Nho K; Nudelman KNH; Faber K; Sun Y; Foroud TM; Estrada K; Apostolova LG; Li QS; Saykin AJ;
    Clin Epigenetics; 2020 Jun; 12(1):84. PubMed ID: 32539856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer's disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer's Disease Neuroimaging Initiative database.
    Abe K; Chiba Y; Hattori S; Yoshimi A; Asami T; Katsuse O; Suda A; Hishimoto A;
    J Neurol Sci; 2020 Sep; 416():116989. PubMed ID: 32603972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in Plasma Amyloid and Tau in a Longitudinal Study of Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
    Chen TB; Lai YH; Ke TL; Chen JP; Lee YJ; Lin SY; Lin PC; Wang PN; Cheng IH
    Dement Geriatr Cogn Disord; 2019; 48(3-4):180-195. PubMed ID: 31991443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease.
    Soares HD; Potter WZ; Pickering E; Kuhn M; Immermann FW; Shera DM; Ferm M; Dean RA; Simon AJ; Swenson F; Siuciak JA; Kaplow J; Thambisetty M; Zagouras P; Koroshetz WJ; Wan HI; Trojanowski JQ; Shaw LM;
    Arch Neurol; 2012 Oct; 69(10):1310-7. PubMed ID: 22801723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics.
    Bos I; Vos S; Vandenberghe R; Scheltens P; Engelborghs S; Frisoni G; Molinuevo JL; Wallin A; Lleó A; Popp J; Martinez-Lage P; Baird A; Dobson R; Legido-Quigley C; Sleegers K; Van Broeckhoven C; Bertram L; Ten Kate M; Barkhof F; Zetterberg H; Lovestone S; Streffer J; Visser PJ
    Alzheimers Res Ther; 2018 Jul; 10(1):64. PubMed ID: 29980228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease.
    Llano DA; Devanarayan V; Simon AJ;
    Alzheimer Dis Assoc Disord; 2013; 27(3):233-43. PubMed ID: 23023094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease.
    Hu WT; Holtzman DM; Fagan AM; Shaw LM; Perrin R; Arnold SE; Grossman M; Xiong C; Craig-Schapiro R; Clark CM; Pickering E; Kuhn M; Chen Y; Van Deerlin VM; McCluskey L; Elman L; Karlawish J; Chen-Plotkin A; Hurtig HI; Siderowf A; Swenson F; Lee VM; Morris JC; Trojanowski JQ; Soares H;
    Neurology; 2012 Aug; 79(9):897-905. PubMed ID: 22855860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Circulating Caprylic Acid with Risk of Mild Cognitive Impairment and Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Cohort.
    Fan L; Zhu X; Borenstein AR; Huang X; Shrubsole MJ; Dugan LL; Dai Q
    J Prev Alzheimers Dis; 2023; 10(3):513-522. PubMed ID: 37357292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers for Early Diagnostic of Mild Cognitive Impairment in Type-2 Diabetes Patients: A Multicentre, Retrospective, Nested Case-Control Study.
    Xu ZP; Yang SL; Zhao S; Zheng CH; Li HH; Zhang Y; Huang RX; Li MZ; Gao Y; Zhang SJ; Zhan PY; Zhang LF; Deng L; Wei S; Liu YC; Ye JW; Ren HJ; Li N; Kong CX; Wang X; Fang L; Zhou QZ; Jiang HW; Li JR; Wang Q; Ke D; Liu GP; Wang JZ
    EBioMedicine; 2016 Mar; 5():105-13. PubMed ID: 27077117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing candidate serum biomarkers for Alzheimer's disease: a longitudinal study.
    Zabel M; Schrag M; Mueller C; Zhou W; Crofton A; Petersen F; Dickson A; Kirsch WM
    J Alzheimers Dis; 2012; 30(2):311-21. PubMed ID: 22426016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of APOE gene with longitudinal changes of CSF amyloid beta and tau levels in Alzheimer's disease: racial differences.
    Xu C; Xiao D; Su BB; Saveron JM; Gamez D; Navia RO; Wang N; Roy U; Adjeroh DA; Wang K;
    Neurol Sci; 2024 Mar; 45(3):1041-1050. PubMed ID: 37759100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.